Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:512401.
doi: 10.1155/2012/512401. Epub 2012 Dec 30.

Controversies in the management and followup of differentiated thyroid cancer: beyond the guidelines

Affiliations

Controversies in the management and followup of differentiated thyroid cancer: beyond the guidelines

Hala Ahmadieh et al. J Thyroid Res. 2012.

Abstract

Thyroid cancer is among the most common endocrine malignancies. Genetic and environmental factors play an important role in the pathogenesis of differentiated thyroid cancer. Both have good prognosis but with frequent recurrences. Cancer staging is an essential prognostic part of cancer management. There are multiple controversies in the management and followup of differentiated thyroid cancer. Debate still exists with regard to the optimal surgical approach but trends toward a more conservative approach, such as lobectomy, are being more favored, especially in papillary thyroid cancer, of tumor sizes less than 4 cm, in the absence of other high-risk suggestive features. Survival of patients with well-differentiated thyroid cancer was adversely affected by lymph node metastases. Prophylactic central LN dissection did improve accuracy in staging and decrease postop TG level, but it had no effect on small-sized tumors. Conservative approach was more applied with regard to the need and dose of radioiodine given postoperatively. There have been several advancements in the management of radioiodine resistant advanced differentiated thyroid cancers. Appropriate followup is required based on risk stratification of patients postoperatively. Many studies are still ongoing in order to reach the optimal management and followup of differentiated thyroid cancer.

PubMed Disclaimer

References

    1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, Ga, USA: American Cancer Society; 2012.
    1. Giusti F, Falchetti A, Franceschelli F, Marini F, Tanini A, Brandi ML. Thyroid cancer: current molecular perspectives. Journal of Oncology. 2010;2010:17 pages.351679 - PMC - PubMed
    1. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology. 2009;20(4):143–146. - PubMed
    1. Tuttle R, Leboeuf R, Shaha AR. Medical management of thyroid cancer: a risk adapted approach. Journal of Surgical Oncology. 2008;97(8):712–716. - PubMed
    1. Lang BHH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Annals of Surgery. 2007;245(3):366–378. - PMC - PubMed

LinkOut - more resources